First, we tested whether the baseline levels of previously identified biomarkers such as tumor PD-L1 expression, the number of neo-antigen–specific T cell clones, and the fraction of TILs correlated with response to pembrolizumab monotherapy. Here, CD274 is linked to neoplasm.